BioSpace News Archive

A while ago, some researchers had suggested that blocking a set of proteins, known as bromodomain and extraterminal proteins, might be a way to fight COVID-19.

According to Vision research Reports, the global 3D laparoscopy imaging systems market was surpassed at USD 3.98 billion in 2021 and is expected to hit around USD 6.5 billion by 2030, growing at a CAGR of 5.6% from 2022 to 2030.

The global Hypertrophic and Keloid Scar Treatment market size is expected to be worth around US$ 20.2 billion by 2030 from valued at US$ 5.8 billion in 2020 and is anticipated to grow at a CAGR of 11.9% during forecast period 2021 to 2030.

The global insulin market size is expected to be worth around USD 23.57 billion by 2030 from valued at USD 20.55 billion in 2021 and anticipated to grow at a CAGR of 1.54% during the forecast period 2022 to 2030.

The global downstream processing market size is predicted to be worth around US$ 24.2 billion by 2030 from valued at US$ 6.8 Bn in 2020, expanding growth at a rapid pace from 2020 to 2030.

According to Vision Research Reports, North America OTC health products market size is expected to be worth around USD 106.9 billion by 2030 and poised to grow at a CAGR of 6.05% during the forecast period 2022 to 2030.

The global small molecule API market size is projected to worth around USD 282.85 billion by 2030 from valued at USD 175.52 billion in 2021, growing at a CAGR of 5.44% during the forecast period 2022 to 2030.

According to Report Study, the global Point Of Care Diagnostics market was surpassed at USD 37.1 billion in 2021 and is expected to hit around USD 68.62 billion by 2030, growing at a CAGR of 7.07% from 2022 to 2030.

The U.S. deep brain stimulation in Parkinson’s disease market was estimated at USD 453.87 million in 2021 and it is expected to surpass around USD 849.71 million by 2030, poised to grow at a CAGR of 7.22% from 2022 to 2030.

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended June 30, 2022, on Tuesday, August 2, 2022 after the close of the market, and provide a corporate update.